6533b86ffe1ef96bd12ce65f

RESEARCH PRODUCT

Molecular Design of the Cαβ Interface Favors Specific Pairing of Introduced TCRαβ in Human T Cells

Christoph HuberMargarete GrabowskiRatna Sari IntanMatthias TheobaldJuergen KuballRalph A. WillemsenRenate EngelPedro RomeroRalf-holger VossPhilippe Guillaume

subject

chemistry.chemical_classificationGeneticsAdoptive cell transferPhage displayImmunologyT-cell receptorhemic and immune systemschemical and pharmacologic phenomenaPeptideBiologyLigand (biochemistry)Cell biologychemistryPairingImmunology and AllergyAvidityBeta (finance)

description

Abstract A promising approach to adoptive transfer therapy of tumors is to reprogram autologous T lymphocytes by TCR gene transfer of defined Ag specificity. An obstacle, however, is the undesired pairing of introduced TCRα- and TCRβ-chains with the endogenous TCR chains. These events vary depending on the individual endogenous TCR and they not only may reduce the levels of cell surface-introduced TCR but also may generate hybrid TCR with unknown Ag specificities. We show that such hybrid heterodimers can be generated even by the pairing of human and mouse TCRα- and TCRβ-chains. To overcome this hurdle, we have identified a pair of amino acid residues in the crystal structure of a TCR that lie at the interface of associated TCR Cα and Cβ domains and are related to each other by both a complementary steric interaction analogous to a “knob-into-hole” configuration and the electrostatic environment. We mutated the two residues so as to invert the sense of this interaction analogous to a charged “hole-into-knob” configuration. We show that this inversion in the CαCβ interface promotes selective assembly of the introduced TCR while preserving its specificity and avidity for Ag ligand. Noteworthily, this TCR modification was equally efficient on both a Mu and a Hu TCR. Our data suggest that this approach is generally applicable to TCR independently of their Ag specificity and affinity, subset distribution, and species of origin. Thus, this strategy may optimize TCR gene transfer to efficiently and safely reprogram random T cells into tumor-reactive T cells.

https://doi.org/10.4049/jimmunol.180.1.391